Walter & Keenan Financial Consulting Co. MI ADV lowered its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 894 shares of the medical research company’s stock after selling 100 shares during the period. Walter & Keenan Financial Consulting Co. MI ADV’s holdings in Thermo Fisher Scientific were worth $263,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Truvestments Capital LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at $29,000. Capital Advisors Ltd. LLC increased its holdings in shares of Thermo Fisher Scientific by 250.0% in the second quarter. Capital Advisors Ltd. LLC now owns 140 shares of the medical research company’s stock valued at $41,000 after buying an additional 100 shares in the last quarter. Focused Wealth Management Inc bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at $44,000. Farmers & Merchants Trust Co of Chambersburg PA increased its holdings in shares of Thermo Fisher Scientific by 168.0% in the first quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 201 shares of the medical research company’s stock valued at $55,000 after buying an additional 126 shares in the last quarter. Finally, Cullen Frost Bankers Inc. bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at $64,000. 88.21% of the stock is currently owned by institutional investors.
In other news, Director C Martin Harris sold 275 shares of the company’s stock in a transaction on Wednesday, June 5th. The shares were sold at an average price of $270.73, for a total value of $74,450.75. Following the transaction, the director now directly owns 6,433 shares of the company’s stock, valued at $1,741,606.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $268.29, for a total transaction of $670,725.00. Following the completion of the transaction, the chief financial officer now directly owns 40,029 shares in the company, valued at $10,739,380.41. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,775 shares of company stock worth $14,986,676. Company insiders own 0.45% of the company’s stock.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, July 24th. The medical research company reported $3.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.01 by $0.03. Thermo Fisher Scientific had a net margin of 14.24% and a return on equity of 17.11%. The company had revenue of $6.32 billion for the quarter, compared to the consensus estimate of $6.31 billion. During the same period in the previous year, the business earned $2.75 EPS. The company’s revenue was up 3.9% on a year-over-year basis. Equities analysts anticipate that Thermo Fisher Scientific Inc. will post 12.23 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, October 15th. Shareholders of record on Tuesday, September 17th will be paid a dividend of $0.19 per share. This represents a $0.76 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Monday, September 16th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 6.83%.
Several research analysts have issued reports on the company. BTIG Research upped their price target on Thermo Fisher Scientific to $320.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Zacks Investment Research raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $299.00 price target on the stock in a report on Wednesday, June 12th. UBS Group upped their price target on Thermo Fisher Scientific from $305.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, May 23rd. Bank of America reaffirmed a “buy” rating and issued a $300.00 price target (up previously from $285.00) on shares of Thermo Fisher Scientific in a report on Tuesday, April 16th. Finally, Argus upped their price target on Thermo Fisher Scientific from $285.00 to $310.00 and gave the company a “buy” rating in a report on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $303.17.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Featured Story: What is the Current Ratio?
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.